AMD, if undiagnosed or diagnosed late, leads to either debilitating loss of sight or blindness. Early detection is therefore vital if the progress of the disease is to be checked – an essential requirement but one that current screening techniques have for years fallen well short of meeting.
RapiDA addresses this problem with an innovative new smart digital screening process that diagnoses the disease at the earliest possible stage, when therapies can be administered to help patients continue to lead full and active lives.
RapiDA has been developed by a University of Manchester spin-out company, Mumac. Its technologies are affordable, easy to operate, have exceptional sensitivity and specificity and provide unique real-time data analysis.
The patented technology behind RapiDA has come from a team with an extremely high level of technical expertise and considerable experience of developing ophthalmic instruments and techniques. Other innovative ophthalmic products are currently in the Mumac pipeline.
